COVID-19 Guide de prise en charge des patients neuromusuclaires

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran)..
Avatar de l’utilisateur

Auteur du sujet
Messages : 6565
Inscription : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
Âge : 64
    Windows 10 Firefox
Genre :
Zodiaque :
Âge : 64

COVID-19 Guide de prise en charge des patients neuromusuclaires

Message par Pboulanger »

Bonjour à tous,

Voici, en anglais, la publication de FILNEMUS sur la  prise en charge COVID des malades atteints de maladies neuromusculaires 
L'outil de traduction du site
permet une traduction automatique de l'ABSTRACT  (le résumé)

Abstract :

In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers.

In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory.

Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2 months concerning treatments usually administered in hospitalization.

NM patients treated with steroid/ immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website.

Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement.

The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD.

In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis.

Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.

Code : Tout sélectionner

Bonne lecture et prenez soin de vous
Vous ne pouvez pas consulter les pièces jointes insérées à ce message.


Revenir à « Documentation »